Review of recent guidelines for the management
of severe sepsis and septic shock

doi:10.1007/s11684-010-0008-7

Front. Med.

2010, Vol. 4

Issue (1) : 54-58 https://doi.org/10.1007/s11684-010-0008-7

Research articles

Review of recent guidelines for the management of severe sepsis and septic shock

Jin-Nong ZHANG MD¹,Bo PENG BA¹,Jamile WOODS MD²,Wei PENG MD, PhD²,

1.Pulmonary Division of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2.Department of Pulmonary and Sleep Medicine, Salt Lake Regional Medical Center, Iasis Healthcare, Salt Lake City, UT 84102, USA;

Download: PDF(93 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Severe sepsis and septic shock affect millions of patients and are major causes of mortality worldwide. Advancements in treatment and disease management led to a decline in in-hospital mortality from 27.8% (1979–1984) to 17.9% (1995 to 2000). In this article, we systemically review recent guidelines for the management of severe sepsis and septic shock published in 2008 by the International Surviving Sepsis Campaign Guidelines Committee. The 2008 Surviving Sepsis guidelines recommend protocolized resuscitation with goals to maintain central venous pressure≥8–12mmHg, mean arterial pressure≥65mmHg, urine output≥0.5mL·kg^−1·h^−1 and central venous oxygen saturation≥70% (or mixed venous≥65%). Further fluid administration, transfusion of packed red blood cells to achieve a hematocrit of≥30% and/or infusion of dobutamine max 20µg·kg^−1·min^−1 are advised if venous O₂ saturations remain below 70%. In patients with decreased ventricular compliance or mechanical ventilation, a target central venous pressure of 12–15mmHg is recommended. Intravenous antibiotic administration within the first hour of recognizing severe sepsis and septic shock is essential, while use of corticosteroids in sepsis is controversial. The mechanisms by which activated protein C improves clinical outcomes in sepsis are unknown. Therapy with activated protein C is approved for patients with severe sepsis and an increased risk of death [Acute Physiology and Chronic Health Evaluation II (APACHE II)>25]. Bicarbonate therapy is discouraged. Intravenous insulin should be used to control hyperglycemia in patients with severe sepsis following stabilization in the intensive care unit.

Keywords sepsis septic shock hemodynamics guidelines

Issue Date: 05 March 2010

Cite this article:

Jin-Nong ZHANG MD,Jamile WOODS MD,PhD, et al. Review of recent guidelines for the management of severe sepsis and septic shock[J]. Front. Med., 2010, 4(1): 54-58.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0008-7
https://academic.hep.com.cn/fmd/EN/Y2010/V4/I1/54

	American College of ChestPhysicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelinesfor the use of innovative therapies in sepsis. Crit Care Med, 1992, 20(6): 864―874
	Levy M M, Fink M P, Marshall J C, Abraham E, Angus D, Cook D, Cohen J, Opal S M, Vincent J L, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SISInternational Sepsis Definitions Conference. Crit Care Med, 2003, 31(4): 1250―1256 doi: 10.1097/01.CCM.0000050454.01978.3B
	Balk R A. Severe sepsis and septic shock. Definitions, epidemiology,and clinical manifestations. Crit CareClin, 2000, 16(2): 179―192 doi: 10.1016/S0749-0704(05)70106-8
	Angus D C, Wax R S. Epidemiologyof sepsis: an update. Crit Care Med, 2001, 29(7 Suppl): S109―116 doi: 10.1097/00003246-200107001-00035
	Martin G S, Mannino D M, Eaton S, Moss M. The epidemiology of sepsis in the United States from1979 through 2000. N Engl J Med, 2003, 348(16): 1546―1554 doi: 10.1056/NEJMoa022139

	Kieft H, Hoepelman A I, Zhou W, Rozenberg-Arska M, Struyvenberg A, Verhoef J. The sepsis syndrome in aDutch university hospital: clinical observations. Arch Intern Med, 1993, 153(19): 2241―2247 doi: 10.1001/archinte.153.19.2241
	Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J. Assessment of the safety and efficacy of the monoclonal anti-tumornecrosis factor antibody fragment, MAK195F, in patients with sepsisand septic shock: a multicenter, randomized, placebo-controlled, dose-rangingstudy. Crit Care Med, 1996, 24(5): 733―742 doi: 10.1097/00003246-199605000-00003
	Pittet D, Thiévent B, Wenzel R P, Li N, Auckenthaler R, Suter P M. Bedside prediction of mortalityfrom bacteremic sepsis: dynamic analysis of ICU patients. Am J Respir Crit Care Med, 1996, 153(2): 684―693
	Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed TherapyCollaborative Group. Early goal-directed therapy in the treatmentof severe sepsis and septic shock. N EngJ Med, 2001, 345(19): 1368―1377 doi: 10.1056/NEJMoa010307
	Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and salinefor fluid resuscitation in the intensive care unit. N Engl J Med, 2004, 350(22): 2247―2256 doi: 10.1056/NEJMoa040232
	Holmes C L, Patel B M, Russell J A, Walley K R. Physiology of vasopressin relevant to management of septicshock. Chest, 2001, 120(3): 989―1002 doi: 10.1378/chest.120.3.989
	Russell J A, Walley K R, Singer J, Gordon A C, Hébert P C, Cooper D J, Holmes C L, Mehta S, Granton J T, Storms M M, Cook D J, Presneill J J, Ayers D; VASST Investigators. Vasopressin versus norepinephrineinfusion in patients with septic shock. N Engl J Med, 2008, 358(9): 877―887 doi: 10.1056/NEJMoa067373
	Holmes C L, Walley K R. Bad medicine:low-dose dopamine in the ICU. Chest, 2003, 123(4): 1266―1275 doi: 10.1378/chest.123.4.1266
	Hamrahian A H, Oseni T S, Arafah B M. Measurements of free cortisol in criticallyill patients. N Engl J Med, 2004, 350(16): 1629―1638 doi: 10.1056/NEJMoa020266
	Absalom A, Pledger D, Kong A. Adrenocortical function incritically ill patients 24 h after a single dose of etomidate. Anaesthesia, 1999, 54(9): 861―867 doi: 10.1046/j.1365-2044.1999.01003.x
	Sprung C L, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss Y G, Benbenishty J, Kalenka A, Forst H, Laterre P F, Reinhart K, Cuthbertson B H, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patientswith septic shock. N Engl J Med, 2008, 358(2): 111―124 doi: 10.1056/NEJMoa071366
	Annane D, Bellissant E, Bollaert P E, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis andseptic shock: a systematic review and meta-analysis. BMJ, 2004, 329(7464): 480 doi: 10.1136/bmj.38181.482222.55
	Annane D, Sébille V, Charpentier C, Bollaert P E, François B, Korach J M, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Effect of treatment withlow doses of hydrocortisone and fludrocortisone on mortality in patientswith septic shock. JAMA, 2002, 288(7): 862―871 doi: 10.1001/jama.288.7.862
	Bernard G R, Vincent J L, Laterre P F, LaRosa S P, Dhainaut J F, Lopez-Rodriguez A, Steingrub J S, Garber G E, Helterbrand J D, Ely E W, Fisher C J Jr; Recombinant human protein C Worldwide Evaluation in SevereSepsis (PROWESS) study group. Efficacy and safety of recombinant activatedprotein C for severe sepsis. N Engl J Med, 2001, 344(10): 699―709 doi: 10.1056/NEJM200103083441001
	Abraham E, Laterre P F, Garg R, Levy H, Talwar D, Trzaskoma B L, François B, Guy J S, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback B G, Macias W L; Administration of Drotrecogin Alfa (Activated) in EarlyStage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated)for adults with severe sepsis and a low risk of death. N Engl J Med, 2005, 353(13): 1332―1341 doi: 10.1056/NEJMoa050935
	Hébert P C, Wells G, Blajchman M A, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized,controlled clinical trial of transfusion in critical care. N Engl J Med, 1999, 340(6): 409―417 doi: 10.1056/NEJM199902113400601
	Corwin H L, Gettinger A, Rodriguez R M, Pearl R G, Gubler K D, Enny C, Colton T, Corwin M J. Efficacy of recombinant humanerythropoietin in the critically ill patient: a randomized double-blind,placebo-controlled trial. Crit Care Med, 1999, 27(11): 2346―2350 doi: 10.1097/00003246-199911000-00004
	The Acute RespiratoryDistress Syndrome Network. Ventilation withlower tidal volumes as compared with traditional tidal volumes foracute lung injury and the acute respiratory distress syndrome. N Engl J Med, 2000, 342(18): 1301―1308 doi: 10.1056/NEJM200005043421801
	National Heart, Lung, and Blood InstituteAcute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann H P, Wheeler A P, Bernard G R, Thompson B T, Hayden D, deBoisblanc B, Connors A F Jr, Hite R D, Harabin A L. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med, 2006, 354(24): 2564―2575
	Truog R D, Campbell M L, Curtis J R, Haas C E, Luce J M, Rubenfeld G D, Rushton C H, Kaufman D C; American Academy of Critical Care Medicine. Recommendations for end-of-lifecare in the intensive care unit: a consensus statement by the AmericanAcademy of Critical Care Medicine. CritCare Med, 2008, 36(3): 953―963 doi: 10.1097/CCM.0B013E3181659096
	Antonelli M, Mercurio G. The 2008 international guidelines for management of severe sepsisand septic shock: merits and weaknesses. Minerva Anestesiol, 2009, 75(1,2): 27―29

[1]	Wei Tian, Bo Liu, Da He, Yajun Liu, Xiaoguang Han, Jingwei Zhao, Mingxing Fan, International Society for Computer Assisted Orthopaedic Surgery. Guidelines for navigation-assisted spine surgery[J]. Front. Med., 2020, 14(4): 518-527.
[2]	Lan Wang,Sen Jiang,Jingyun Shi,Sugang Gong,Qinhua Zhao,Rong Jiang,Ping Yuan,Bigyan Pudasaini,Jing He,Zhicheng Jing,Jinming Liu. Clinical characteristics of pulmonary hypertension in bronchiectasis[J]. Front. Med., 2016, 10(3): 336-344.
[3]	Yong G. Peng,Haibo Song,E. Wang,Weipeng Wang,Jin Liu. Essential training steps to achieving competency in the basic intraoperative transesophageal echocardiography examination for Chinese anesthesiologists[J]. Front. Med., 2015, 9(1): 123-128.
[4]	Jonathan Skupsky,Ke-Qin Hu. Current hepatitis B treatment guidelines and future research directions[J]. Front. Med., 2014, 8(2): 145-157.
[5]	Bao-Zhu Yuan,Junzhi Wang. The regulatory sciences for stem cell-based medicinal products[J]. Front. Med., 2014, 8(2): 190-200.
[6]	Xiao Liu, Hui Ren, Daizhi Peng. Sepsis biomarkers: an omics perspective[J]. Front Med, 2014, 8(1): 58-67.
[7]	HUA Rong, SUN Yongwei, WU Zhiyong. Effects of combined procedure and devascularization alone on hyperdynamics of the portal venous system in patients with portal hypertension[J]. Front. Med., 2008, 2(3): 244-247.

Viewed

Full text

Abstract

Cited

Shared

Discussed